Infliximab effective in treatment of plaque-type psoriasis
As reported in the British Journal of Dermatology, of patients with plaque-type psoriasis (n=660) treated with infliximab (5 mg/kg) at weeks 0, 2, and 6, then q 8 weeks through week 50, 56.8% achieved PASI 75, 71.6% of whom maintained the response through week 98. Of patients who achieved PASI 75 by week 14, 64.7% maintained the response through week 50. Of patients who did not achieve PASI 75 by week 50, 66.3% achieved PASI 75 by week 98.
sCD40L suggests sub-clinical atherosclerosis in psoriasis
As reported in the International Journal of Dermatology, sCD40L levels are elevated and brachial artery flow-mediated dilation is decreased in patients with chronic plaque-type psoriasis (n=56) without known cardiovascular disease compared to healthy controls.
Down-regulation of IGF-1 involved in male pattern baldness
As reported in Experimental Dermatology, secretion of IGF-1, IGFBP-2, and IGFBP-4 is decreased in the dermal papillae of balding hair follicles compared to non-balding hair follicles.